AhR modulator-1 is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. It inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. It also possesses anti-estrogenic properties in rat uterus.

AhR modulator-1 (6-MCDF; 0.1-10 μM; 48-96 hours; ASPC-1 cells) treatment exhibits dose-dependent growth inhibitory effects with growth inhibitory effects of 26, 43 and 99% at concentrations of 0.1, 1 and 10 μM, respectively [2].

AhR modulator-1 (0-40 mg/kg; p.o.; daily; for 12 weeks; C57BL/6-Tg(TRAMP)8247Ng/J mice) treatment reduces the frequency of pelvic lymph node metastasis in mice fed the 40 mg/kg diet. And serum VEGF concentrations are also reduced. Prostate tumor incidence and size are not significantly reduced [1].